Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Condition:   Head and Neck Neoplasms
Interventions:   Biological: Pembrolizumab 200 mg;   Radiation: Radiotherapy 60 Gray/day;   Radiation: Radiotherapy 66 Gray/day;   Radiation: Radiotherapy 70 Gray/day;   Drug: Cisplatin 100 mg/m^2
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting

https://ift.tt/2RAjVoN